2H0A Stock Overview
An early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Exicure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$1.30 |
| 52 Week Low | US$0.32 |
| Beta | 1.23 |
| 1 Month Change | -18.45% |
| 3 Month Change | -21.35% |
| 1 Year Change | -44.30% |
| 3 Year Change | -98.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2H0A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -1.6% | -0.9% |
| 1Y | -44.3% | -26.8% | 4.5% |
Return vs Industry: 2H0A underperformed the German Biotechs industry which returned -26.8% over the past year.
Return vs Market: 2H0A underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 2H0A volatility | |
|---|---|
| 2H0A Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2H0A's share price has been volatile over the past 3 months.
Volatility Over Time: 2H0A's weekly volatility has decreased from 19% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 7 | Paul Kang | www.exicuretx.com |
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company’s preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Exicure, Inc. Fundamentals Summary
| 2H0A fundamental statistics | |
|---|---|
| Market cap | €3.78m |
| Earnings (TTM) | €2.74m |
| Revenue (TTM) | €20.09m |
1.4x
P/E Ratio0.2x
P/S RatioIs 2H0A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2H0A income statement (TTM) | |
|---|---|
| Revenue | US$21.77m |
| Cost of Revenue | US$16.06m |
| Gross Profit | US$5.72m |
| Other Expenses | US$2.75m |
| Earnings | US$2.97m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 26.27% |
| Net Profit Margin | 13.64% |
| Debt/Equity Ratio | 0% |
How did 2H0A perform over the long term?
See historical performance and comparison